Sunitinib free base

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100791

CAS#: 557795-19-4 (free base)

Description: Sunitinib free base is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib malate salt was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib inhibits cellular signaling by targeting multiple receptor tyrosine kinases (RTKs). The simultaneous inhibition of these targets therefore reduces tumor vascularization and triggers cancer cell apoptosis and thus results in tumor shrinkage. Sunitinib also inhibits CD117 (c-KIT), the receptor tyrosine kinase that (when improperly activated by mutation) drives the majority of gastrointestinal stromal cell tumors.

Chemical Structure

Sunitinib free base
CAS# 557795-19-4 (free base)

Theoretical Analysis

MedKoo Cat#: 100791
Name: Sunitinib free base
CAS#: 557795-19-4 (free base)
Chemical Formula: C22H27FN4O2
Exact Mass: 398.2118
Molecular Weight: 398.48
Elemental Analysis: C, 66.31; H, 6.83; F, 4.77; N, 14.06; O, 8.03

Price and Availability

Size Price Availability Quantity
1.0g USD 75.0 Same day
5.0g USD 350.0 Same day
10.0g USD 550.0 Same day
50.0g USD 1950.0 Same day
100.0g USD 2950.0 Same day
200.0g USD 4950.0 2 Weeks
500.0g USD 7950.0 2 Weeks
1.0kg USD 12650.0 2 Weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 341031-54-7 (malate)   557795-19-4 (free base)   342641-94-5   1126641-10-8 (maleate)   1221149-36-5 (acetate)   1327155-72-5 (HCl)   1275588-72-1 (mesylate)   1332306-95-2 (oxalate)    

Synonym: SU11248; SU-11248; SU 11248; SU011248; sunitinib. US brand name: Sutent.

IUPAC/Chemical Name: (Z)-N-(2-(diethylamino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide


InChi Code: InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-


Appearance: Yellow solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 398.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Carlisle B, Demko N, Freeman G, Hakala A, MacKinnon N, Ramsay T, Hey S, London AJ, Kimmelman J. Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. J Natl Cancer Inst. 2015 Nov 7;108(1). pii: djv292. doi: 10.1093/jnci/djv292. Print 2016 Jan. Review. PubMed PMID: 26547927.

2: Bianconi M, Faloppi L, Del Prete M, Giampieri R, Bittoni A, Lopez-Beltran A, Scarpelli M, Cheng L, Scartozzi M, Cascinu S, Montironi R. Predictive factors for sunitinib treatment response in advanced renal cell carcinoma: are we really making steps forward? Anal Quant Cytopathol Histpathol. 2015 Feb;37(1):3-13. Review. PubMed PMID: 26072629.

3: Abdel-Rahman O, Fouad M. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature. Crit Rev Oncol Hematol. 2015 May;94(2):238-50. doi: 10.1016/j.critrevonc.2015.01.006. Epub 2015 Jan 19. Review. PubMed PMID: 25638704.

4: Kalra S, Rini BI, Jonasch E. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Ann Oncol. 2015 Jul;26(7):1300-4. doi: 10.1093/annonc/mdv030. Epub 2015 Jan 26. Review. PubMed PMID: 25628443; PubMed Central PMCID: PMC4490228.

5: Tzogani K, Skibeli V, Westgaard I, Dalhus M, Thoresen H, Slot KB, Damkier P, Hofland K, Borregaard J, Ersbøll J, Salmonson T, Pieters R, Sylvester R, Mickisch G, Bergh J, Pignatti F. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist. 2015 Feb;20(2):196-201. doi: 10.1634/theoncologist.2014-0177. Epub 2015 Jan 23. Review. PubMed PMID: 25616431; PubMed Central PMCID: PMC4319625.

6: Raymond E, Faivre S. Learning experiences with sunitinib continuous daily dosing in patients with pancreatic neuroendocrine tumours. Curr Oncol. 2014 Dec;21(6):309-17. doi: 10.3747/co.21.1647. Review. PubMed PMID: 25489258; PubMed Central PMCID: PMC4257114.

7: Abdel-Rahman O, Fouad M. Risk of mucocutaneous toxicities in patients with solid tumors treated with sunitinib: a critical review and meta analysis. Expert Rev Anticancer Ther. 2015 Jan;15(1):129-41. doi: 10.1586/14737140.2015.985660. Epub 2014 Dec 8. Review. PubMed PMID: 25482593.

8: Lee CH, Motzer RJ. Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. Urol Oncol. 2015 Jun;33(6):275-9. doi: 10.1016/j.urolonc.2014.10.012. Epub 2014 Nov 24. Review. PubMed PMID: 25465298.

9: Joosten SC, Hamming L, Soetekouw PM, Aarts MJ, Veeck J, van Engeland M, Tjan-Heijnen VC. Resistance to sunitinib in renal cell carcinoma: From molecular mechanisms to predictive markers and future perspectives. Biochim Biophys Acta. 2015 Jan;1855(1):1-16. doi: 10.1016/j.bbcan.2014.11.002. Epub 2014 Nov 11. Review. PubMed PMID: 25446042.

10: Thiery-Vuillemin A, Mouillet G, Pouessel D, Barthelemy P, Caty A, Sebbagh S, Vanno YA, Laplaige P, Cheverau C, Ravaud A. [Alternative prescription schedules of sunitinib in metastatic kidney cancer: from the underground to the light?]. Bull Cancer. 2014 Sep;101(9):832-40. doi: 10.1684/bdc.2014.2020. Review. French. PubMed PMID: 25295955.

11: Guida FM, Santoni M, Conti A, Burattini L, Savini A, Zeppola T, Caricato M, Cascinu S, Tonini G, Santini D. Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2014 Dec;92(3):208-17. doi: 10.1016/j.critrevonc.2014.07.006. Epub 2014 Aug 6. Review. PubMed PMID: 25151214.

12: Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis. Crit Rev Oncol Hematol. 2014 Dec;92(3):194-207. doi: 10.1016/j.critrevonc.2014.06.003. Epub 2014 Jul 1. Review. PubMed PMID: 25028151.

13: Kim S, Ding W, Zhang L, Tian W, Chen S. Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials. Onco Targets Ther. 2014 May 12;7:719-28. doi: 10.2147/OTT.S61388. eCollection 2014. Review. PubMed PMID: 24872713; PubMed Central PMCID: PMC4026584.

14: Porta C, Paglino C, Grünwald V. Sunitinib re-challenge in advanced renal-cell carcinoma. Br J Cancer. 2014 Sep 9;111(6):1047-53. doi: 10.1038/bjc.2014.214. Epub 2014 May 6. Review. PubMed PMID: 24800947; PubMed Central PMCID: PMC4453836.

15: Mitchell CC, Parikh OA. Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib. Patient Prefer Adherence. 2014 Apr 22;8:503-11. doi: 10.2147/PPA.S38989. eCollection 2014. Review. PubMed PMID: 24790418; PubMed Central PMCID: PMC4003261.

16: Imbulgoda A, Heng DY, Kollmannsberger C. Sunitinib in the treatment of advanced solid tumors. Recent Results Cancer Res. 2014;201:165-84. doi: 10.1007/978-3-642-54490-3_9. Review. PubMed PMID: 24756791.

17: Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer. 2015 Jan 1;136(1):1-10. doi: 10.1002/ijc.28715. Epub 2014 Feb 7. Review. PubMed PMID: 24415642.

18: Bilbao-Meseguer I, Jose BS, Lopez-Gimenez LR, Gil MA, Serrano L, Castaño M, Sautua S, Basagoiti AD, Belaustegui A, Baza B, Baskaran Z, Bustinza A. Drug interactions with sunitinib. J Oncol Pharm Pract. 2015 Feb;21(1):52-66. doi: 10.1177/1078155213516158. Epub 2014 Jan 8. Review. PubMed PMID: 24403097.

19: Pons F, Bellmunt J. Sunitinib malate in the treatment of urothelial cancer. Expert Opin Investig Drugs. 2014 Jan;23(1):115-24. doi: 10.1517/13543784.2014.853740. Epub 2013 Nov 4. Review. PubMed PMID: 24188025.

20: Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer. 2014 Aug 15;135(4):763-73. doi: 10.1002/ijc.28544. Epub 2013 Nov 18. Review. PubMed PMID: 24127298.